WESTLAKE VILLAGE, Calif., April 6, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that on March 27, 2015, the Compensation Committee of the Company's Board of Directors granted five new employees options to purchase an aggregate of 40,000 shares of the Company's common stock. The exercise price of each option was $48.18, the closing trading price on the date of grant. The stock options were granted pursuant to the Company's 2014 Employment Commencement Incentive Plan, which was approved by the Company's Board of Directors in August 2014 under Rule 5653(c)(4) of The Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. Find more information at www.kythera.com.